公开(公告)号：US11576986B2

公开(公告)日：2023-02-14

申请号：US16869771

申请日：2020-05-08

Applicant: Janssen Biotech, Inc.

Inventor： Rhys Salter ,  Vadim Dudkin ,  Fengbin Song ,  Wei Zhang ,  Shalom Goldberg ,  John Keith

IPC: A61K51/02 ,  A61K51/04 ,  A61K51/10

Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

公开(公告)号：US20210363177A1

公开(公告)日：2021-11-25

申请号：US17324150

申请日：2021-05-19

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley

IPC: C07K1/107 ,  A61K47/68 ,  A61K47/54 ,  A61K47/62

Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.

公开(公告)号：US11072663B2

公开(公告)日：2021-07-27

申请号：US16227597

申请日：2018-12-20

Applicant: Janssen Biotech, Inc.

Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78 ,  A61K39/00

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US20200325210A1

公开(公告)日：2020-10-15

申请号：US16840479

申请日：2020-04-06

Applicant: Janssen Biotech, Inc.

Inventor： Mark Anderson ,  Ricardo Attar ,  Michael Diem ,  Shalom Goldberg ,  Linus Hyun ,  Steven Jacobs ,  Alastair King ,  Donna Klein ,  Sheri Moores ,  Karyn O'Neil ,  Kristen Picha

IPC: C07K14/78 ,  C07K14/71 ,  C12N15/64 ,  C12N15/09 ,  C12N15/63 ,  C07K19/00

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US20190184028A1

公开(公告)日：2019-06-20

申请号：US16218990

申请日：2018-12-13

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Andrew Elias ,  Shalom Goldberg ,  Donna Klein ,  Elise Kuhar ,  Tricia Lin ,  Lavanya Peddada ,  Karyn O'Neil ,  Kristen Wiley

IPC: A61K47/68 ,  A61P35/00 ,  C07K14/78 ,  A61P37/06 ,  B82Y5/00 ,  A61K47/69 ,  A61K47/64 ,  A61K47/42 ,  A61K31/7105

CPC classification number: A61K47/6807 ,  A61K31/7105 ,  A61K47/42 ,  A61K47/6415 ,  A61K47/6925 ,  A61K47/6929 ,  A61P35/00 ,  A61P37/06 ,  B82Y5/00 ,  C07K14/78

Abstract: A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain with a toxin or nanoparticle containing an active polynucleotide, such as an ASO or siRNA molecule. A fibronectin type III (FN3) domain-nucleic acid conjugate is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain to a nucleic acid (e.g., ASO or siRNA). The nanoparticle complex, nucleic acid conjugate or FN3 domain toxin conjugate may be used in the treatment of diseases and conditions, for example, oncology or auto-immune indications.